Axen Cancer Panel 1, cfDNA (liquid biopsy)
Coming soon
The same 88-gene panel run on cell-free DNA from a blood sample, for when tissue is limited or unavailable.
| Clinical purpose | Detects tumour-derived variants circulating in blood. Useful when a tissue biopsy is not possible or when a less invasive sample is preferred. |
|---|---|
| Sample type | Blood (cell-free DNA) |
| Genes / regions covered | 88 genes for SNVs and indels, plus ALK, RET and ROS1 fusions: ABL1, AKT1, AKT3, ALK, APC, AR, ATM, AXL, BRAF, BRCA1, BRCA2, CCND1, CDH1, CDK4, CDK6, CDKN2A, CEBPA, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, EZH2, FANCA, FANCC, FANCF, FANCG, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MAP2K4, MET, MLH1, MPL, MTOR, MYC, MYCN, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3CA, PIK3R1, PPARG, PTEN, PTPN11, RAF1, RB1, RET, ROS1, RUNX1, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL, WT1 |
| Intended use | Somatic profiling from blood. A negative liquid biopsy does not exclude a tumour variant. |
| Approximate turnaround | Confirmed when you enquire |
| Report type | NGS report with sequencing quality metrics, SNV/indel, fusion and copy-number sections |
| Ordering requirements | Confirmed when you enquire |
| Price | Confirmed when you enquire |
Turnaround, price and sample requirements are confirmed when you enquire, so you never rely on an outdated figure. Whether this test is appropriate is a decision for the treating oncologist.